Medicare Rx Plan Negotiations Will Avert Drug Industry “Windfall” – PhRMA
The Pharmaceutical Research & Manufacturers of America disagrees with the prediction that Medicare's assumption of "dual eligibles" will be a financial boon for drug makers
You may also be interested in...
State Medicaid agencies are considering ways to use the upcoming Medicare prescription drug coverage program to enhance their drug price negotiating power
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials